Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Conditions
Brief summary
RATIONALE: Panobinostat and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving panobinostat together with everolimus and to see how well they work in treating patients with metastatic or unresectable renal cell cancer that does not respond to treatment with sunitinib malate or sorafenib tosylate
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability and determine the recommended dosing for the combination of LBH589 and Everolimus in patients with metastatic renal cell carcinoma. (Phase I) II. To assess the preliminary evidence of tumor response in patients treated with LBH589 and Everolimus. (Phase I) III. To evaluate the effect of LBH589 and Everolimus on the progression-free survival event rate. (Phase II) IV. To determine the clinical response rate of LBH589 and Everolimus in patients with metastatic renal cell carcinoma. (Phase II) SECONDARY OBJECTIVES: I. To determine the toxicity of the combination of LBH589 and Everolimus in patients with metastatic renal cell carcinoma. (Phase II) II. To evaluate the effect of LBH589 and Everolimus on time-to-tumor-progression (TTP), disease-free survival and overall survival. (Phase II) III. To assess the pharmacodynamic effects of LBH589 and Everolimus in peripheral blood mononuclear cells (PBMNC) and tumor that are accessible before and after treatment, if available. (Phase II) IV. To evaluate the modulation of tumor metabolism and blood in patients treated with LBH589 and Everolimus by FDG and 015 water PET/CT scan. (Phase II) OUTLINE: This is a dose-escalation study of panobinostat and everolimus, followed by a phase II study. Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for at least 4 weeks.
Interventions
DRUGpanobinostat
Given orally
DRUGeverolimus
Given orally
OTHERlaboratory biomarker analysis
Correlative studies
OTHERpharmacological study
Correlative studies
Correlative studies
OTHERmass spectrometry
Correlative studies
OTHERenzyme-linked immunosorbent assay
Correlative studies
OTHERimmunohistochemistry staining method
Correlative studies
Sponsors
Novartis
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed metastatic or unresectable renal cell carcinoma * Predominant clear cell component is required * Patients must have metastatic disease which has progressed on or within 6 months of stopping treatment with VEGFR receptor tyrosine kinase inhibitors * Previous therapy with bevacizumab, interleukin 2, or interferon alpha is also permitted * Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Serum albumin \>= 3g/dL * AST/SGOT and ALT/SGPT =\< 2.5 x upper limit of normal (ULN) * Serum bilirubin =\< 1.5 x ULN * Serum creatinine =\< 1.5 x ULN or 24-hour creatinine clearance \>= 50 ml/min * Serum potassium \>= LLN * Serum phosphorous \>= LLN * Serum total calcium (corrected for serum albumin) or serum ionized calcium \>= LLN * Serum magnesium \>= LLN * TSH and free T4 within normal limits (WNL); patients may be on thyroid hormone replacement * ANC \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Hb \> 9 g/dL * INR \< 1.3 (or \< 3 on anticoagulants) * Fasting serum cholesterol =\< 300 mg/dL OR =\< 7.75 mmol/L AND fasting triglycerides =\< 2.5 x ULN (in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication * Baseline MUGA or ECHO must demonstrate LVEF \>= the lower limit of the institutional normal * ECOG Performance Status of =\< 2
Exclusion criteria
* Pure papillary and chromophobe renal cell carcinoma, collecting duct tumors and transitional cell carcinoma are not eligible * Prior treatment with a pan-HDAC or mTOR inhibitor * Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.) * Patients who have had a major surgery of significant traumatic injury within 4 weeks of start of study drug and who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study * Prior treatment with any investigational drug within the preceding 4 weeks * Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed * Patients should not receive immunization with attenuated live vaccines within one weeks of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus (Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY2a typhoid vaccines) * Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases * Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: * 1\) Symptomatic congestive heart failure of New York Heart Association Class III or 4 * 2\) Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease * 3\) Concomitant use of drugs with a risk of causing torsades de pointes * 4\) Severely impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air * 5\) Uncontrolled diabetes as defined by fasting serum glucose \> 1.5 x ULN; optimal glycemic control should be achieved before starting trial therapy * 6\) Active (acute or chronic) or uncontrolled severe infections * 7\) Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis; a detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients; HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection * A known HIV seropositivity * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) * Patients with an active, bleeding diathesis * Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug by both sexes * Adults of reproductive potential who are not using effective birth control methods; if barrier contraceptive are being used, these must be continued throughout this trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception * Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to administration of everolimus * Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus) * Patients with a known hypersensitivity to everolimus (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients * History of noncompliance to medical regimens * Male patient whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment * Patients unwilling to or unable to comply with the protocol * Patients currently receiving strong or moderate CYP3A4 inhibitors or inducers; patients should not begin study drugs until at least 72 hours after the last dose (or longer, as indicated) of the inhibitor or inducer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | The time from registration to documentation of disease progression up to 3 years | 6 month PFS survival rate. Calculated as the total number of failures (deaths or progression) divided by the total follow-up or exposure time of patients on study. Assessed using Kaplan Meier and Proportional Hazards. |
| Number of Participants With Clinical Response | The time from registration up to 3 years | Number of participants with clinical response. Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors ver 1.0 Committee \[JNCI 92(3):205-216, 2000\]. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST ver. 1.0 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With an Adverse Event. | The time from registration up to 3 years | Number of participants with an adverse event. Please refer to the adverse event reporting for more detail. |
| Median Progression Free Survival | The time from registration up to 3 years | Median progression free survival. Assessed using Kaplan Meier and Proportional Hazards. |
| 6-month Overall Survival Rate | The time from registration up to 3 years | 6-month overall survival rate |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
panobinostat: Given orally
everolimus: Given orally
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
liquid chromatography: Correlative studies
mass spectrometry: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
immunohistochemistry staining method: Correlative studies | 26 |
| Total | 26 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Physician Decision | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Arm I: Oral Panobinostat and Oral Everolimus |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 12 Participants |
| Age, Categorical Between 18 and 65 years | 14 Participants |
| Age, Continuous | 62.4 years STANDARD_DEVIATION 10.6 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 22 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 26 / 26 |
| serious Total, serious adverse events | 9 / 26 |
Outcome results
Primary
Number of Participants With Clinical Response
Number of participants with clinical response. Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors ver 1.0 Committee \[JNCI 92(3):205-216, 2000\]. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST ver. 1.0 criteria.
Time frame: The time from registration up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus | Number of Participants With Clinical Response | 0 Participants |
Primary
Progression-free Survival (PFS)
6 month PFS survival rate. Calculated as the total number of failures (deaths or progression) divided by the total follow-up or exposure time of patients on study. Assessed using Kaplan Meier and Proportional Hazards.
Time frame: The time from registration to documentation of disease progression up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus | Progression-free Survival (PFS) | 28 percentage of participants |
Secondary
6-month Overall Survival Rate
6-month overall survival rate
Time frame: The time from registration up to 3 years
Population: All treated and eligible patients. Assessed using Kaplan Meier and Proportional Hazards.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus | 6-month Overall Survival Rate | 96 percentage of participants |
Secondary
Median Progression Free Survival
Median progression free survival. Assessed using Kaplan Meier and Proportional Hazards.
Time frame: The time from registration up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus | Median Progression Free Survival | 5.3 months |
Secondary
Number of Participants With an Adverse Event.
Number of participants with an adverse event. Please refer to the adverse event reporting for more detail.
Time frame: The time from registration up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I: Oral Panobinostat and Oral Everolimus | Number of Participants With an Adverse Event. | 26 Participants |